In order to limit ECM reprogramming and collagen remodeling associated with therapy resistance and relapse in melanoma, we tested the effect of the anti‐fibrotic drug nintedanib (BIBF1120), a triple inhibitor of PDGFR, VEGFR, and FGFR used to treat idiopathic pulmonary fibrosis (IPF) in combination with BRAFi/MEKi in a syngeneic model of transplanted murine YUMM1.7 Braf‐mutant melanoma (Meeth et al, 2016). The gene discussed is PDGFRB; the disease is pulmonary fibrosis.